News Releases Keyword Search Year None202420232022202120202019201820172016 Mar-11-2020 Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Feb-06-2020 Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Dec-12-2019 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium Dec-11-2019 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma Dec-09-2019 Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting Dec-03-2019 Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium Nov-21-2019 Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference Nov-14-2019 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting Nov-11-2019 Oncternal Therapeutics to Present at Stifel Healthcare Conference Nov-07-2019 Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Page 13 Current page 14 Page 15 Page 16 Page 17 Next page next › Last page last »